Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Geletneky, Karsten [VerfasserIn]   i
 Hajda, Jacek [VerfasserIn]   i
 Beelte, Birgit [VerfasserIn]   i
 Capper, David [VerfasserIn]   i
 Bartsch, Andreas J. [VerfasserIn]   i
 Neumann, Jan-Oliver [VerfasserIn]   i
 Schöning, Tilman [VerfasserIn]   i
 Hüsing, Johannes [VerfasserIn]   i
 Deimling, Andreas von [VerfasserIn]   i
 Daniel, Volker [VerfasserIn]   i
 Unterberg, Andreas [VerfasserIn]   i
Titel:Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial
Verf.angabe:Karsten Geletneky, Jacek Hajda, Assia L. Angelova, Barbara Leuchs, David Capper, Andreas J. Bartsch, Jan-Oliver Neumann, Tilman Schöning, Johannes Hüsing, Birgit Beelte, Irina Kiprianova, Mandy Roscher, Rauf Bhat, Andreas von Deimling, Wolfgang Brück, Alexandra Just, Veronika Frehtman, Stephanie Löbhard, Elena Terletskaia-Ladwig, Jeremy Fry, Karin Jochims, Volker Daniel, Ottheinz Krebs, Michael Dahm, Bernard Huber, Andreas Unterberg, and Jean Rommelaere
E-Jahr:2017
Jahr:24 August 2017
Umfang:15 S.
Fussnoten:Gesehen am 02.05.2018
Titel Quelle:Enthalten in: Molecular therapy
Ort Quelle:Amsterdam : Elsevier, 2000
Jahr Quelle:2017
Band/Heft Quelle:25(2017), 12, Seite 2620-2634
ISSN Quelle:1525-0024
Abstract:Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first phase I/IIa clinical trial of an oncolytic parvovirus in recurrent glioblastoma patients. H-1PV (escalating dose) was administered via intratumoral or intravenous injection. Tumors were resected 9 days after treatment, and virus was re-administered around the resection cavity. Primary endpoints were safety and tolerability, virus distribution, and maximum tolerated dose (MTD). Progression-free and overall survival and levels of viral and immunological markers in the tumor and peripheral blood were also investigated. H-1PV treatment was safe and well tolerated, and no MTD was reached. The virus could cross the blood-brain/tumor barrier and spread widely through the tumor. It showed favorable pharmacokinetics, induced antibody formation in a dose-dependent manner, and triggered specific T cell responses. Markers of virus replication, microglia/macrophage activation, and cytotoxic T cell infiltration were detected in infected tumors, suggesting that H-1PV may trigger an immunogenic stimulus. Median survival was extended in comparison with recent meta-analyses. Altogether, ParvOryx01 results provide an impetus for further H-1PV clinical development.
DOI:doi:10.1016/j.ymthe.2017.08.016
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1016/j.ymthe.2017.08.016
 Volltext: http://www.sciencedirect.com/science/article/pii/S1525001617303787
 DOI: https://doi.org/10.1016/j.ymthe.2017.08.016
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:clinical trial
 glioblastoma
 oncolytic parvovirus
 tumor microenvironment
K10plus-PPN:1572510722
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68248365   QR-Code
zum Seitenanfang